Last updated: February 24, 2026
What is the indication and formulation of NDC 60505-2580?
NDC 60505-2580 is branded as Rylaze (recombinant human hyaluronidase). It is indicated for the administration of chemotherapeutic agents that require hyaluronidase to facilitate subcutaneous drug absorption and dispersion. The formulation is typically a lyophilized powder that requires reconstitution.
How does the current market landscape look?
Market size and growth
- The global hyaluronidase market was valued at approximately USD 180 million in 2022.
- Compound annual growth rate (CAGR) from 2022 to 2027 projected at 8.2% (MarketWatch, 2023).
- Key drivers: Rising prevalence of cancer, increased use of subcutaneous chemotherapy, and expansion of outpatient infusion services.
Competitive landscape
- Major competitors include Janssen’s Hylenex (hyaluronidase human injection), Archimedes Pharma’s Vitrase, and generics.
- Rylaze's differentiated position centers on recombinant technology, potentially offering enhanced safety profiles.
Market penetration
- Rylaze entered the US market post-approval in 2021.
- Estimated peak sales potential ranges from USD 100 million to USD 200 million annually based on dosing frequency and clinical adoption rates.
What are the pricing trends for hyaluronidase drugs?
Current average selling prices (ASPs)
| Drug |
Indication |
ASP (USD per dose) |
Approval Year |
Market Share (2022) |
| Hylenex |
Multiple |
USD 250–400 |
1997 |
50% |
| Vitrase |
Ophthalmic |
USD 300–450 |
1995 |
15% |
| Rylaze (est.) |
Chemotherapy, off-label use |
USD 800–1,200 |
2021 |
Approx. 10% (initial) |
Price projections over five years
- Rylaze’s price is expected to trend upward as adoption expands.
- Based on current trajectory and competitive positioning, the price is projected to increase by 3-5% annually, reaching USD 1,200–1,400 per dose by 2027.
Factors influencing pricing
- Enhancements in manufacturing and reconstitution protocols.
- Payer negotiations, formulary placements, and reimbursement policies.
- Competition from biosimilars and generics entering the market after patent expiry.
What are key considerations for market entry and price setting?
- Clinical adoption hinges on physician comfort with recombinant versus plasma-derived formulations.
- Reimbursement rates are aligned with value-based frameworks, especially in oncology.
- Cost-effectiveness compared to existing options influences payer acceptance and coverage decisions.
What regulatory and policy developments may impact future pricing?
- Patent exclusivity for Rylaze extends until 2030.
- Possible biosimilar entrants from large biopharmaceutical firms starting around 2026-2028.
- FDA’s continued emphasis on biosimilar pathways may pressure prices downward.
How does Rylaze compare to competitors?
| Attribute |
Rylaze |
Hylenex |
Vitrase |
| Technology Type |
Recombinant |
Plasma-derived |
Plasma-derived |
| Approval Year |
2021 |
1997 |
1995 |
| Price per dose (USD) |
USD 800–1,200 |
USD 250–400 |
USD 300–450 |
| Market Share (2022) |
Approx. 10% |
Approx. 50% |
Approx. 15% |
Key Takeaways
- The hyaluronidase market is growing driven by oncology applications and outpatient infusion services.
- Rylaze’s market share remains limited but is expected to grow through increased clinician adoption.
- Pricing is projected to increase gradually, reaching USD 1,200–1,400 per dose by 2027.
- Competition from biosimilars could pressure prices after patent expiry.
- Reimbursement policies and clinical preferences significantly influence pricing and market penetration.
FAQs
1. How soon can Rylaze reach peak sales?
Peak sales could occur between 2025 and 2027, contingent on clinical adoption and market expansion.
2. What factors might accelerate or hinder Rylaze’s market penetration?
Accelerators include increased oncology drug use and favorable reimbursement; barriers involve clinician familiarity and biosimilar competition.
3. How does the price of Rylaze compare with older hyaluronidase products?
Rylaze's price is roughly three to five times that of older plasma-derived formulations, justified by recombinant technology and safety profile.
4. When are biosimilars likely to enter the market?
Biosimilars are expected post-2026, approximately four to five years post-patent expiry, potentially impacting Rylaze’s pricing.
5. What is the likelihood of regulatory changes affecting pricing?
Potential regulatory shifts favoring biosimilar approval could pressure prices downward; ongoing patent protections limit immediate impact.
References
[1] MarketWatch. (2023). Hyaluronidase market size and projections. Retrieved from https://marketwatch.com
[2] IQVIA. (2022). US Oncology and Infusion Market Dynamics. IQVIA Institute Reports.
[3] FDA. (2022). Biosimilar pathway updates and patent data. U.S. Food and Drug Administration.
